For the third quarter of 2026, analysts expect Quantum BioPharma Ltd. to report a consensus loss of $0.50 per share on $0.00 in revenue, as the stock trades at $2.21 compared to a 12-month analyst target of $8.00.
The primary focus for investors is the clinical progression of the company’s lead compound, Lucid-MS, following recent FDA clearance to begin a Phase 2 trial for progressive multiple sclerosis.
The company recently entered into a strategic start-up agreement with Thermo Fisher Scientific to implement these trials, marking a critical transition from regulatory approval to operational execution. Management has been focused on reducing cash burn and strengthening its equity position ahead of these significant R&D milestones.